Skip to content

Daily Breeze

60°F
Tuesday, January 6th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

8.710 +0.300 (+3.57%)
Streaming Delayed Price Updated: 3:06 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Why Is Tharimmune (THAR) Stock Down 8% Today? ↗
Tharimmune stock is falling after the company announced a reverse stock split for THAR shares that goes into effect later today. 
Via InvestorPlace
News headline image
Earnings Outlook For Aligos Therapeutics ↗
 
Via Benzinga
News headline image
Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today? ↗
Aligos Therapeutics stock is falling alongside news of a secondary offering for ALGS that it won't see any proceeds of the sales from. 
Via InvestorPlace
News headline image
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket ↗
Shares of Applied UV, Inc. (NASDAQ: AUVI) shares jumped in pre-market trading after the company reported third-quarter results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning! 
Via InvestorPlace
News headline image
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule,
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
November 16 Event to feature KOL perspective on Emerging HBV Therapies 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Why Aligos Therapeutics (ALGS) Stock Is Nosediving ↗
Aligos Therapeutics Inc (NASDAQ: ALGS) shares are trading lower by 15.8% to $0.64 Monday afternoon after the company announced $92 million in private placement financing 
Via Benzinga
News headline image
Aligos Therapeutics Announces $92 Million Private Placement Financing
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal ↗
LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales. Meanwhile, Amoytop... 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
News headline image
Why NeoGames Shares Are Trading Higher By 121%; Here Are 20 Stocks Moving Premarket ↗
Gainers NeoGames S.A. (NASDAQ: NGMS) shares surged 121% to $28.38 in pre-market trading as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.